BIAF insider filings
bioAffinity Technologies, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen BIAF transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 2 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 11 legs across 1 filing by 1 insider — 138,244 shares, $1,039,671 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 11 legs across 1 filing by 1 insider — 162,219 shares, $1,175,048 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 6.
- Largest priced transaction: sale of 41,529 shares @ $6.45 ($267,721) by HRT FINANCIAL LP, filed 2026-11-19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| HRT FINANCIAL LP — 10% owner | 2 | 11 legs · 138,244 sh · $1,039,671 | 11 legs · 162,219 sh · $1,175,048 | 6 |
Recent insider filings — bioAffinity Technologies, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 4 | HRT FINANCIAL LP — 10% owner | Purchase (P): 18,929 @ $8.59 · Sale (S): 7,077 @ $8.63 · Purchase (P): 7,509 @ $7.91 · Purchase (P): 11,002 @ $8.14 · Sale (S): 11,129 @ $7.94 · Sale (S): 10,859 @ $8.11 · +22 more | EDGAR |
| 2026-11-19 | 3 | HRT FINANCIAL LP — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2025-01-14 | 4 | Reveles Xavier Trinidad — Chief Operating Officer | Grant/award (A): 21,604 @ $0 | EDGAR |
| 2025-01-14 | 4 | Zannes Timothy P — Secretary, EVP, Gen. Counsel | Grant/award (A): 8,641 @ $0 | EDGAR |
| 2025-01-14 | 4 | Edwards James Michael — VP and CFO | Grant/award (A): 6,172 @ $0 | EDGAR |
| 2025-01-14 | 4 | Zannes Maria — President & CEO, Director | Grant/award (A): 37,037 @ $0 | EDGAR |
| 2025-01-14 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 14,814 @ $0 | EDGAR |
| 2024-11-05 | 4 | Edwards James Michael — VP and CFO | Grant/award (A): 100,000 @ $0 | EDGAR |
| 2024-07-02 | 4 | Joyce Roby — Director | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-07-02 | 4 | Anderson Robert A. — Director | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-07-02 | 4 | Platt Jamie — Director | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-07-02 | 4 | Zannes Maria — President & CEO, Director | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-07-02 | 4 | Rubin Gary D — Director, 10% owner Harvey Sandler Revocable Trust — 10% owner | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-07-02 | 4 | DIAMOND STUART — Director | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-07-02 | 4 | KNIGHT PETER S — Director | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-07-02 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 33,784 @ $0 | EDGAR |
| 2024-06-14 | 4 | Platt Jamie — Director | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-06-14 | 4 | Joyce Roby — Director | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-06-14 | 4 | Anderson Robert A. — Director | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-06-14 | 4 | Zannes Maria — President & CEO, Director | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-06-14 | 4 | Rubin Gary D — Director, 10% owner Harvey Sandler Revocable Trust — 10% owner | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-06-14 | 4 | DIAMOND STUART — Director | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-06-14 | 4 | KNIGHT PETER S — Director | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-06-14 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 8,296 @ $0 | EDGAR |
| 2024-04-24 | 4 | Zannes Timothy P — Secretary, EVP, Gen. Counsel | Option exercise (M): 64,848 @ $1.16 · Tax withholding (F): 29,031 @ $2.58 · Option exercise (M): 64,848 (derivative) @ $0 | EDGAR |
| 2024-04-24 | 4 | Zannes Maria — President & CEO | Option exercise (M): 64,848 @ $1.16 · Tax withholding (F): 28,264 @ $2.65 · Option exercise (M): 64,848 (derivative) @ $0 | EDGAR |
| 2024-04-24 | 4 | GIRGENTI STEVEN — Director | Option exercise (M): 64,848 @ $1.16 · Tax withholding (F): 33,438 @ $2.24 · Option exercise (M): 64,848 (derivative) @ $0 | EDGAR |
| 2024-03-29 | 4 | Anderson Robert A. — Director | Option exercise (M): 64,848 @ $1.16 · Option exercise (M): 64,848 (derivative) @ $0 | EDGAR |
| 2024-03-29 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 39,474 @ $1.52 | EDGAR |
| 2024-02-02 | 4 | Zannes Timothy P — Secretary, EVP, Gen. Counsel | Grant/award (A): 6,688 @ $0 | EDGAR |
| 2024-02-02 | 4 | Reveles Xavier Trinidad — Chief Operating Officer | Grant/award (A): 16,720 @ $0 | EDGAR |
| 2024-02-02 | 4 | Rebel Vivienne I — Chief Sci. & Med. Officer, EVP | Grant/award (A): 31,847 @ $0 | EDGAR |
| 2024-02-02 | 4 | Dougherty Michael Philip — Chief Financial Officer | Grant/award (A): 31,847 @ $0 | EDGAR |
| 2024-02-02 | 4 | Zannes Maria — President, CEO, Director | Grant/award (A): 23,885 @ $0 | EDGAR |
| 2024-02-02 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 11,943 @ $0 | EDGAR |
| 2024-01-24 | 4 | Joyce Roby — Director Joyce Living Trust | Grant/award (A): 11,867 @ $1.58 · Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2024-01-24 | 4 | Platt Jamie — Director | Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2024-01-24 | 4 | Anderson Robert A. — Director | Grant/award (A): 11,867 @ $1.58 · Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2024-01-24 | 4 | Zannes Maria — President, CEO, Director | Grant/award (A): 11,867 @ $1.58 · Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2024-01-24 | 4 | Rubin Gary D — Director, 10% owner Harvey Sandler Revocable Trust — 10% owner | Grant/award (A): 11,867 @ $1.58 · Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2024-01-24 | 4 | DIAMOND STUART — Director | Grant/award (A): 11,867 @ $1.58 · Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2024-01-24 | 4 | Meghji Mohsin Y — Director | Grant/award (A): 11,867 @ $1.58 | EDGAR |
| 2024-01-24 | 4 | KNIGHT PETER S — Director | Grant/award (A): 11,867 @ $1.58 · Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2024-01-24 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 11,867 @ $1.58 · Grant/award (A): 12,668 @ $1.48 | EDGAR |
| 2023-08-11 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 8,227 @ $2.28 · Grant/award (A): 9,920 @ $1.89 · Grant/award (A): 10,245 @ $1.83 · Grant/award (A): 26,315 @ $2.28 | EDGAR |
| 2023-07-06 | 4 | Rubin Gary D — Director, 10% owner Harvey Sandler Revocable Trust — 10% owner | Grant/award (A): 8,227 @ $2.28 · Grant/award (A): 9,920 @ $1.89 · Grant/award (A): 10,245 @ $1.83 | EDGAR |
| 2023-07-06 | 4 | DIAMOND STUART — Director | Grant/award (A): 8,227 @ $2.28 · Grant/award (A): 9,920 @ $1.89 · Grant/award (A): 10,245 @ $1.83 | EDGAR |
| 2023-07-06 | 4 | Meghji Mohsin Y — Director | Grant/award (A): 8,227 @ $2.28 · Grant/award (A): 9,920 @ $1.89 · Grant/award (A): 10,245 @ $1.83 | EDGAR |
| 2023-07-06 | 4 | KNIGHT PETER S — Director | Grant/award (A): 8,227 @ $2.28 · Grant/award (A): 9,920 @ $1.89 · Grant/award (A): 10,245 @ $1.83 | EDGAR |
| 2023-07-06 | 4 | GIRGENTI STEVEN — Executive Chairman, Director | Grant/award (A): 8,227 @ $2.28 · Grant/award (A): 9,920 @ $1.89 · Grant/award (A): 10,245 @ $1.83 | EDGAR |
Recent 8-K events — bioAffinity Technologies, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-20 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-17 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-29 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — bioAffinity Technologies, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-300194 (S-1) — latest: Initial registration (S-1), filed 2026-11-20
GET https://api.filingpulse.io/v1/insider-trades?ticker=BIAF returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs